Latest News
VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101
Read Press Release View All NewsAV-101, our oral N-methyl-D-aspartate (NMDA) receptor glycine B (GlyB) antagonist, belongs to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators having the potential to treat depression, including Major Depressive Disorder (MDD), faster than current FDA-approved antidepressants commonly known as SSRIs and SNRIs, which target the neurotransmitters serotonin and/or norepinephrine, respectively. AV-101 is in Phase 2 development, initially for the adjunctive treatment of MDD. ELEVATE is our ongoing Phase 2, randomized, double-blind, multi-center, placebo-controlled clinical trial designed to evaluate the efficacy and safety of adjunctive use of oral AV-101 for MDD in patients with an inadequate response to standard antidepressant therapy with either an FDA-approved selective SSRI or SNRI.
Our highly experienced Management Team, Board of Directors, and CNS Clinical and Regulatory Advisory Board have a proven track record of developing innovative medicines to treat a wide range of CNS diseases and disorders.
Meet Our Team